SCIENTURE Celebrates FDA Approval of Arbli™ as a Major Advancement in Hypertension Treatment
SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) is excited to announce a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for its New Drug Application (NDA) for SCN-102, now branded as Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL. This groundbreaking formulation is set to transform how hypertension is treated, particularly for patients who require liquid medication.
The Significance of Arbli™ in Hypertension Management
Hypertension, or high blood pressure, affects nearly half of the adult population in the U.S., translating into approximately 119.9 million individuals. Traditional treatments have primarily revolved around solid tablet formulations, but the approval of Arbli™ introduces a unique solution that caters specifically to patients seeking an easier, more efficient way to manage their condition.
A New Era for Patients
Arbli™ is recognized as the first FDA-approved ready-to-use oral liquid formulation of losartan available on the U.S. market. It is targeted at individuals over the age of six who are living with hypertension and are at risk of stroke or suffering from diabetic nephropathy due to type 2 diabetes. This innovative solution has been meticulously designed to offer both safety and effectiveness, providing a much-needed alternative for patients who struggle with traditional oral solid medications.
Enhanced Dosing and Safety Features
The proprietary formulation of Arbli™ eliminates the complications often associated with compounding solid medications into liquid form. By avoiding the potential for inconsistencies—such as mistakes during the crushing of tablets—Arbli™ presents a safer option for patients dependent on precise dosing. Furthermore, it boasts an extended shelf-life of 18 months when stored at room temperature, setting a new standard in liquid medication stability.
Market Insights: The Demand for Liquid Hypertension Solutions
The market for losartan potassium reached approximately $1.5 billion, demonstrating a consistent demand for effective hypertension treatments. The introduction of Arbli™ allows for a new wave of accessibility for both physicians and patients, addressing the critical need for innovative healthcare solutions in this widespread condition. According to recent data, the total annual sales for losartan in the U.S. reached around $292 million with an impressive prescription volume of 68 million, spotlighting the necessity for a versatile alternative.
What Healthcare Professionals Are Saying
Shankar Hariharan, CEO of Scienture, LLC, expressed his enthusiasm about the approval, stating, "The approval of Arbli™ exemplifies our deep commitment to develop high value products that address unique and underserved patient needs. We are thrilled to introduce a brand that combines convenience with efficacy—ideal for those who require an oral liquid formulation." Narasimhan Mani, the President of Scienture, LLC, noted, "We expect to launch Arbli™ in the U.S. marketplace in the third quarter, presenting a transformative therapy option that caters to the growing need for liquid medications."
Additional Information on Arbli™ and Safety Considerations
Arbli™ has been formulated as a peppermint-flavored suspension that eliminates the need for refrigeration, making it easier for patients to manage their medication. However, it's essential to recognize that the use of Arbli™ is accompanied by specific safety information. Notably, pregnant women should not take Arbli™, as it can have serious effects on fetal health.
Safety Precautions
Safety information highlights that patients should refrain from co-administering Arbli™ with certain medications, particularly aliskiren in patients with diabetes, and those with severe hepatic impairment should avoid its use. Common side effects may include dizziness and upper respiratory infections, reminding patients to always consult with their healthcare providers.
For further inquiries regarding Arbli™, patients and healthcare professionals can contact Scienture Holdings at (866) 468-6535 or interact at their website.
About Scienture Holdings, Inc.
SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) is dedicated to improving patient care through pioneering pharmaceutical products. With subsidiaries that encompass both specialty medications and comprehensive distribution systems, Scienture aims to fulfill unmet medical needs while offering unique solutions that improve the lives of patients and caregivers alike. As the company progresses, more innovative products are expected to be developed and brought into the healthcare market.
Frequently Asked Questions
What is Arbli™ and how is it used?
Arbli™ is a liquid oral suspension of losartan potassium approved by the FDA for treating hypertension, particularly in patients over six years old.
What are the benefits of using Arbli™?
This product provides an easy-to-use liquid form of losartan, offering better dosing precision and avoiding complications from crushing tablets.
How long can Arbli™ be stored?
Arbli™ has a shelf life of 18 months when stored at room temperature, with plans for extension after further stability data submission.
Are there any safety concerns associated with Arbli™?
Yes, Arbli™ is not recommended for pregnant women and has specific contraindications with certain medications.
How can patients obtain Arbli™?
Arbli™ is expected to be commercially available in the U.S. beginning Q3 2025, allowing access to those in need.
